Country: Malta
Language: English
Source: Medicines Authority
zoledronic acid monohydrate 5 mg
1 A Pharma GmbH
M05BA08
zoledronic acid monohydrate
solution for infusion
Authorised
2013-07-16
Page 1 of 8 PACKAGE LEAFLET: INFORMATION FOR THE USER ZOLEDRONIC ACID SANDOZ 5 MG/100 ML SOLUTION FOR INFUSION Zoledronic acid READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any of the side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Zoledronic acid Sandoz is and what it is used for 2. What you need to know before you are given Zoledronic acid Sandoz 3. How Zoledronic acid Sandoz is given 4. Possible side effects 5. How to store Zoledronic acid Sandoz 6. Contents of the pack and other information 1. WHAT ZOLEDRONIC ACID SANDOZ IS AND WHAT IT IS USED FOR Zoledronic acid Sandoz contains the active substance zoledronic acid. It belongs to a group of medicines called bisphosphonates and is used to treat post-menopausal women and men with osteoporosis or osteoporosis caused by treatment with steroids, and Paget’s disease of the bone. OSTEOPOROSIS Osteoporosis is a disease that involves the thinning and weakening of the bones and is common in women after the menopause, but can also occur in men. At the menopause, a woman’s ovaries stop producing the female hormone oestrogen, which helps keep bones healthy. Following the menopause bone loss occurs, bones become weaker and break more easily. Osteoporosis could also occur in men and women because of Read the complete document
Page 1 of 19 1. NAME OF THE MEDICINAL PRODUCT Zoledronic acid Sandoz 5 mg/100ml solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each bottle of 100 ml solution for infusion contains 5 mg zoledronic acid. Each ml of the solution contains 0.05 mg zoledronic acid anhydrous, corresponding to 0.0533 mg zoledronic acid monohydrate. Excipient with known effect: This medicinal product contains 0.306 mmol (or 7.04 mg) sodium per dose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for infusion Clear and colourless solution (isotonic, pH between 6.0 – 7.0). 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of osteoporosis • in post-menopausal women • in men at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy • in post-menopausal women • in men at increased risk of fracture. Treatment of Paget’s disease of the bone in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology For the treatment of post-menopausal osteoporosis, osteoporosis in men and the treatment of osteoporosis associated with long-term systemic glucocorticoid therapy, the recommended dose is a single intravenous infusion of 5 mg zoledronic acid administered once a year. The optimal duration of bisphosphonate treatment for osteoporosis has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of zoledronic acid on an individual patient basis, particularly after 5 or more years of use. Page 2 of 19 In patients with a recent low-trauma hip fracture, it is recommended to give the Zoledronic Read the complete document